Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.37 |
| ▸ | RAB9A | P51151 | 10/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | STAT1 | P42224 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 2/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13487371 | 0.94 | NPC1 (0.37) | NPC1RAB9AJAK2SMN1; SMN2TP53 | |
| SCHEMBL13487287 | 0.92 | MET (0.36) | NPC1RAB9AJAK2SMN1; SMN2TP53 | |
| SCHEMBL13487179 | 0.91 | NPC1 (0.36) | NPC1RAB9AJAK2SMN1; SMN2TP53 | |
| SCHEMBL13487905 | 0.89 | NPC1 (0.38) | NPC1RAB9AJAK2SMN1; SMN2TP53 | |
| SCHEMBL13487115 | 0.89 | ACACA (0.42) | SMN1; SMN2DHODHKMT2AMEN1KDM4E | |
| SCHEMBL13487519 | 0.88 | NPC1 (0.37) | NPC1RAB9AJAK2SMN1; SMN2TP53 | |
| SCHEMBL13487060 | 0.88 | MEN1 (0.36) | NPC1RAB9AJAK2SMN1; SMN2TP53 | |
| SCHEMBL13487105 | 0.87 | NPC1 (0.36) | NPC1RAB9ASMN1; SMN2TP53DHODH | |
| SCHEMBL13487122 | 0.86 | ESR1 (0.36) | SMN1; SMN2DHODHMAPT | |
| SCHEMBL13488135 | 0.85 | NPC1 (0.40) | NPC1RAB9AJAK2SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-25 | — | — | US | disclosed |
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OCIAD1, OCIAD2, ORMDL3 | NPC1 1139/4885RAB9A 3244/4885JAK2 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.